Monoglycosylated SARS-CoV-2 receptor binding domain fused with HA < sub > stem < /sub > -scaffolded protein vaccine confers broad protective immunity against SARS-CoV-2 and influenza viruses

This study demonstrated that HSSRmg produced using a monoglycosylation process and combined with the JR300 adjuvant elicits superior cross-strain immune responses against SARS-CoV-2 and influenza viruses in mice compared with S-2P. JR300-adjuvanted HSSRmg has great potential as a coronavirus-influenza vaccine that provides dual protection against SARS-CoV-2 and influenza infections.PMID:37984568 | DOI:10.1016/j.antiviral.2023.105759

Source: Antiviral Research - November 20, 2023 Category: Virology Authors: Chia-Ying Wu Yung-Chieh Tseng Shao-En Kao Li-Yang Wu Jen-Tzu Hou Yu-Chih Yang Pei-Wen Hsiao Juine-Ruey Chen Source Type: research